- Home
- Media Center
- Press releases
- Corporate
Corporate
New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO®Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits
Findings Add to Existing Research Showing XARELTO® Cost-Savings Value Across Multiple Indications
Johnson & Johnson Announces Definitive Agreement To Collaborate With Google To Advance Surgical Robotics
Strategic Collaboration Designed to Develop New Technologies that Offer Surgeons and Health Care Systems Greater Accuracy, Cost Efficiency and Better Outcomes for Patients
Phase 3 Study with IMBRUVICA® (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression
Independent Data Monitoring Committee determines HELIOS study meets its primary endpoint of progression-free survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma at a pre-planned interim analysis
Johnson & Johnson Announces Formation of New Health and Wellness Platform Designed to Transform Health Care Delivery and Improve the Patient Experience
New Patient Athlete™ Program Demonstrates Comprehensive Approach to Driving Sustained Behavior Change and Improved Outcomes
Janssen Launches Three New Research Platforms Focused on Redefining Healthcare
New Focus in Disease Prevention, Disease Interception, and the Microbiome to Propel Scientific Innovation
Depuy Synthes Companies Acquires Olive Medical Corporation
Visualization Platform Technology and Expertise to Broaden Arthroscopy Portfolio
Johnson & Johnson Partners with Save the Children to Help Millions of Children over the Next Three Years
Save the Children named as Enterprise Wide Global Partner
Johnson & Johnson Announces Completion Of Alios Biopharma Acquisition
Further Strengthens Existing Pipeline to Address Infectious Diseases